Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy.

Content Provider	Europe PMC
Author	Murphy, P S Viviers, L Abson, C Rowland, I J Brada, M Leach, M O Dzik-Jurasz, A S K
Copyright Year	2004
Abstract	Assessment of low-grade glioma treatment response remains as much of a challenge as the treatment itself. Proton magnetic resonance spectroscopy (1H-MRS) and imaging were incorporated into a study of patients receiving temozolomide therapy for low-grade glioma in order to evaluate and monitor tumour metabolite and volume changes during treatment. Patients (n=12) received oral temozolomide (200 mg m−2 day−1) over 5 days on a 28-day cycle for 12 cycles. Response assessment included baseline and three-monthly magnetic resonance imaging studies (pretreatment, 3, 6, 9 and 12 months) assessing the tumour size. Short (TE (echo time)=20 ms) and long (TE=135 ms) echo time single voxel spectroscopy was performed in parallel to determine metabolite profiles. The mean tumour volume change at the end of treatment was −33% (s.d.=20). The dominant metabolite in long echo time spectra was choline. At 12 months, a significant reduction in the mean choline signal was observed compared with the pretreatment (P=0.035) and 3-month scan (P=0.021). The reduction in the tumour choline/water signal paralleled tumour volume change and may reflect the therapeutic effect of temozolomide.
ISSN	00070920
Journal	British Journal of Cancer
Volume Number	90
PubMed Central reference number	PMC2410174
Issue Number	4
PubMed reference number	14970853
e-ISSN	15321827
DOI	10.1038/sj.bjc.6601593
Language	English
Publisher	Nature Publishing Group
Publisher Date	2004-02-01
Access Restriction	Open
Rights License	This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. Copyright © 2004 Cancer Research UK
Subject Keyword	magnetic resonance spectroscopy low-grade glioma temozolomide treatment response
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology